Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

por Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Publicado 2022

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?

por Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Quaglino, Pietro, Ribero, Simone
Publicado 2022

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study

por Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Zenone, Mattia, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Publicado 2022

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population

por Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Merli, Martina, Agostini, Andrea, Ribero, Simone, Quaglino, Pietro
Publicado 2022

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

por Mastorino, Luca, Susca, Sara, Megna, Matteo, Siliquini, Niccolò, Quaglino, Pietro, Ortoncelli, Michela, Avallone, Gianluca, Rubatto, Marco, Fabbrocini, Gabriella, Dapavo, Paolo, Ribero, Simone
Publicado 2022